Theravance Biopharma's YUPELRI sales increased six percent

Theravance Biopharma reported a 6% increase in YUPELRI net sales, reaching over $58 million in the first quarter of 2025. This growth reflects strong demand and favorable pricing. The company's Q1 earnings call highlighted YUPELRI's performance, driven by a 48% year-over-year increase in hospital doses. Theravance is also progressing with the CYPRESS trial. Executives discussed the company's financial results and ongoing clinical trials during the earnings call. They also provided updates on the CYPRESS trial's enrollment progress.